Patents by Inventor Avinash S
Avinash S has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190048033Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an ether (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.Type: ApplicationFiled: October 18, 2018Publication date: February 14, 2019Applicant: Achillion Pharmaceuticals, Inc.Inventors: Jason Allan Wiles, Venkat Rao Gadhachanda, Godwin Pais, Akihiro Hashimoto, Qiuping Wang, Dawei Chen, Xiangzhu Wang, Atul Agarwal, Milind Deshpande, Avinash S. Phadke
-
Publication number: 20190031692Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.Type: ApplicationFiled: October 1, 2018Publication date: January 31, 2019Applicant: Achillion Pharmaceuticals, Inc.Inventors: Jason Allan Wiles, Avinash S. Phadke, Xiangzhu Wang, Dawei Chen, Akihiro Hashimoto, Venkat Rao Gadhachanda, Godwin Pais, Qiuping Wang, Atul Agarwal, Milind Deshpande
-
Patent number: 10189869Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof, wherein R12 or R13 on the A group is an amino substituent (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.Type: GrantFiled: March 20, 2017Date of Patent: January 29, 2019Assignee: Achillion Pharmaceuticals, Inc.Inventors: Venkat Rao Gadhachanda, Akihiro Hashimoto, Godwin Pais, Qiuping Wang, Dawei Chen, Xiangzhu Wang, Atul Agarwal, Milind Deshpande, Jason Allan Wiles, Avinash S. Phadke
-
Publication number: 20190023729Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.Type: ApplicationFiled: September 24, 2018Publication date: January 24, 2019Applicant: Achillion Pharmaceuticals, Inc.Inventors: Jason Allan Wiles, Venkat Rao Gadhachanda, Qiuping Wang, Godwin Pais, Akihiro Hashimoto, Dawei Chen, Xiangzhu Wang, Atul Agarwal, Milind Deshpande, Avinash S. Phadke
-
Patent number: 10138225Abstract: Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an amide substituent (R32) are provided. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein are capable of reducing the excessive activation of complement.Type: GrantFiled: August 25, 2016Date of Patent: November 27, 2018Assignee: Achillion Pharmaceuticals, Inc.Inventors: Jason Allan Wiles, Avinash S. Phadke, Milind Deshpande, Atul Agarwal, Dawei Chen, Venkat Rao Gadhachanda, Akihiro Hashimoto, Godwin Pais, Qiuping Wang, Xiangzhu Wang
-
Patent number: 10131304Abstract: A bumper assembly includes a bumper cover, a bumper reinforcement beam spaced apart from the bumper cover, a low speed bumper energy absorber that extends along a front surface of the bumper reinforcement beam between the bumper cover and the bumper reinforcement beam, and a low force energy absorber positioned below the low speed bumper energy absorber. The low force energy absorber includes a body portion extending along the front surface of the bumper reinforcement beam and one or more air deflectors extending from an upper surface of the body portion between the low speed bumper energy absorber and the bumper cover. The one or more air deflectors are configured to substantially isolate a portion of the bumper assembly from air leakage through the bumper assembly.Type: GrantFiled: February 9, 2017Date of Patent: November 20, 2018Assignee: TOYOTA MOTOR ENGINEERING & MANUFACTURING NORTH AMERICA, INC.Inventors: Jeremiah T. Hammer, Avinash S. Phadatare, Robert J. Marks, David N. Evans, Majid Shaikh
-
Patent number: 10131305Abstract: A bumper assembly includes a bumper cover including one or more air deflectors extending inward from the bumper cover, a bumper reinforcement beam positioned rearward of the bumper cover, and a low speed bumper energy absorber that extends along a front surface of the bumper reinforcement beam between the bumper cover and the bumper reinforcement beam. The one or more air deflectors extend from the bumper cover toward the low speed bumper energy absorber at an oblique angle relative to a front face of the low speed bumper energy absorber to substantially isolate a portion of the bumper assembly from air leakage through the bumper assembly.Type: GrantFiled: February 9, 2017Date of Patent: November 20, 2018Assignee: TOYOTA MOTOR ENGINEERING & MANUFACTURING NORTH AMERICA, INC.Inventors: Robert J. Marks, David N. Evans, Avinash S. Phadatare, Jeremiah T. Hammer
-
Patent number: 10131303Abstract: A bumper assembly includes a bumper cover, a bumper reinforcement beam spaced apart from the bumper cover, and a low speed bumper energy absorber that extends along a front surface of the bumper reinforcement beam between the bumper cover and the bumper reinforcement beam. The low speed bumper energy absorber includes a body portion extending along the front surface of the bumper reinforcement beam, wherein at least a portion of the body portion is space apart from the bumper cover, and one or more air deflectors extending between the body portion and the bumper cover, wherein the one or more air deflectors substantially isolate a portion of the bumper assembly from air leakage through the bumper assembly.Type: GrantFiled: February 9, 2017Date of Patent: November 20, 2018Assignee: TOYOTA MOTOR ENGINEERING & MANUFACTURING NORTH AMERICA, INC.Inventors: Robert J. Marks, David N. Evans, Jeremiah T. Hammer, Avinash S. Phadatare, Majid Shaikh
-
Publication number: 20180305375Abstract: Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors of Factor D described herein reduce the excessive activation of complement.Type: ApplicationFiled: June 15, 2018Publication date: October 25, 2018Applicant: Achillion Pharmaceuticals, Inc.Inventors: Jason Allan Wiles, Avinash S. Phadke, Milind Deshpande, Atul Agarwal, Dawei Chen, Venkat Rao Gadhachanda, Akihiro Hashimoto, Godwin Pais, Qiuping Wang, Xiangzhu Wang
-
Patent number: 10106563Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an ether (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.Type: GrantFiled: August 14, 2017Date of Patent: October 23, 2018Assignee: Achillion Pharmaecuticals, Inc.Inventors: Jason Allan Wiles, Venkat Rao Gadhachanda, Godwin Pais, Akihiro Hashimoto, Qiuping Wang, Dawei Chen, Xiangzhu Wang, Atul Agarwal, Milind Deshpande, Avinash S. Phadke
-
Publication number: 20180298043Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof, wherein R12 or R13 on the A group is an alkyne (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.Type: ApplicationFiled: June 12, 2018Publication date: October 18, 2018Applicant: Achillion Pharmaceuticals, Inc.Inventors: Jason Allan Wiles, Godwin Pais, Akihiro Hashimoto, Venkat Rao Gadhachanda, Qiuping Wang, Dawei Chen, Xiangzhu Wang, Atul Agarwal, Milind Deshpande, Avinash S. Phadke
-
Publication number: 20180291046Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof, wherein R12 or R13 on the A group is an alkyne (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.Type: ApplicationFiled: June 12, 2018Publication date: October 11, 2018Applicant: Achillion Pharmaceuticals, Inc.Inventors: Jason Allan Wiles, Godwin Pais, Akihiro Hashimoto, Venkat Rao Gadhachanda, Qiuping Wang, Dawei Chen, Xiangzhu Wang, Atul Agarwal, Milind Deshpande, Avinash S. Phadke
-
Publication number: 20180291047Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof, wherein R12 or R13 on the A group is an alkyne (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.Type: ApplicationFiled: June 12, 2018Publication date: October 11, 2018Applicant: Achillion Pharmaceuticals, Inc.Inventors: Jason Allan Wiles, Godwin Pais, Akihiro Hashimoto, Venkat Rao Gadhachanda, Qiuping Wang, Dawei Chen, Xiangzhu Wang, Atul Agarwal, Milind Deshpande, Avinash S. Phadke
-
Patent number: 10092584Abstract: Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduce the excessive activation of complement.Type: GrantFiled: August 25, 2016Date of Patent: October 9, 2018Assignee: Achillion Pharmaceuticals, Inc.Inventors: Jason Allan Wiles, Avinash S. Phadke, Milind Deshpande, Atul Agarwal, Dawei Chen, Venkat Rao Gadhachanda, Akihiro Hashimoto, Godwin Pais, Qiuping Wang, Xiangzhu Wang
-
Patent number: 10087203Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.Type: GrantFiled: September 11, 2017Date of Patent: October 2, 2018Assignee: Achillion Pharmaceuticals, Inc.Inventors: Jason Allan Wiles, Avinash S. Phadke, Xiangzhu Wang, Dawei Chen, Akihiro Hashimoto, Venkat Rao Gadhachanda, Godwin Pais, Qiuping Wang, Atul Agarwal, Milind Deshpande
-
Patent number: 10081645Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D comprising formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.Type: GrantFiled: September 21, 2017Date of Patent: September 25, 2018Assignee: Achillion Pharmaceuticals, Inc.Inventors: Jason Allan Wiles, Venkat Rao Gadhachanda, Qiuping Wang, Godwin Pais, Akihiro Hashimoto, Dawei Chen, Xiangzhu Wang, Atul Agarwal, Milind Deshpande, Avinash S. Phadke
-
Publication number: 20180222421Abstract: A bumper assembly includes a bumper cover including one or more air deflectors extending inward from the bumper cover, a bumper reinforcement beam positioned rearward of the bumper cover, and a low speed bumper energy absorber that extends along a front surface of the bumper reinforcement beam between the bumper cover and the bumper reinforcement beam. The one or more air deflectors extend from the bumper cover toward the low speed bumper energy absorber at an oblique angle relative to a front face of the low speed bumper energy absorber to substantially isolate a portion of the bumper assembly from air leakage through the bumper assembly.Type: ApplicationFiled: February 9, 2017Publication date: August 9, 2018Applicant: Toyota Motor Engineering & Manufacturing North America, Inc.Inventors: Robert J. Marks, David N. Evans, Avinash S. Phadatare, Jeremiah T. Hammer
-
Publication number: 20180222420Abstract: A bumper assembly includes a bumper cover, a bumper reinforcement beam spaced apart from the bumper cover, a low speed bumper energy absorber that extends along a front surface of the bumper reinforcement beam between the bumper cover and the bumper reinforcement beam, and a low force energy absorber positioned below the low speed bumper energy absorber. The low force energy absorber includes a body portion extending along the front surface of the bumper reinforcement beam and one or more air deflectors extending from an upper surface of the body portion between the low speed bumper energy absorber and the bumper cover. The one or more air deflectors are configured to substantially isolate a portion of the bumper assembly from air leakage through the bumper assembly.Type: ApplicationFiled: February 9, 2017Publication date: August 9, 2018Applicant: Toyota Motor Engineering & Manufacturing North America, Inc.Inventors: Jeremiah T. Hammer, Avinash S. Phadatare, Robert J. Marks, David N. Evans, Majid Shaikh
-
Publication number: 20180222419Abstract: A bumper assembly includes a bumper cover, a bumper reinforcement beam spaced apart from the bumper cover, and a low speed bumper energy absorber that extends along a front surface of the bumper reinforcement beam between the bumper cover and the bumper reinforcement beam. The low speed bumper energy absorber includes a body portion extending along the front surface of the bumper reinforcement beam, wherein at least a portion of the body portion is space apart from the bumper cover, and one or more air deflectors extending between the body portion and the bumper cover, wherein the one or more air deflectors substantially isolate a portion of the bumper assembly from air leakage through the bumper assembly.Type: ApplicationFiled: February 9, 2017Publication date: August 9, 2018Applicant: Toyota Motor Engineering & Manufacturing North America, Inc.Inventors: Robert J. Marks, David N. Evans, Jeremiah T. Hammer, Avinash S. Phadatare, Majid Shaikh
-
Publication number: 20180201580Abstract: Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I? and I?? or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.Type: ApplicationFiled: February 26, 2018Publication date: July 19, 2018Applicant: Achillion Pharmaceuticals, Inc.Inventors: Jason Allan Wiles, Avinash S. Phadke, Milind Deshpande, Atul Agarwal, Dawei Chen, Venkat Rao Gadhachanda, Akihiro Hashimoto, Godwin Pais, Qiuping Wang, Xiangzhu Wang, William Greenlee